![](/img/cover-not-exists.png)
No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up
Calza, Leonardo, Borderi, Marco, Colangeli, Vincenzo, Borioni, Aurora, Coladonato, Simona, Granozzi, Bianca, Viale, PierluigiJournal:
Infectious Diseases
DOI:
10.1080/23744235.2019.1707279
Date:
December, 2019
File:
PDF, 915 KB
2019